 |
Rockville, Maryland, USA and Suzhou, ChinaMay 13, 2026 /PRNewswire/ — Ascentage Pharma (Nasdaq: AAPG; HKEX: 6855), a leading biopharmaceutical company dedicated to developing innovative drugs in oncology and other areas, announced that 17 clinical progress updates on its core products will be presented at the 2026 European Hematology Association (EHA) Annual Congress. These include the company’s original first-in-class drug, China’s first approved third-generation BCR-ABL inhibitor, Olverembatinib (brand name: Nailike®; development code: HQP1351), and the company’s original first-in-class drug, China’s first domestically developed selective Bcl-2 inhibitor, Lisaftoclax (brand name: Lishengtuo®; development code: APG-2575). Among these, eight will be poster presentations. The congress will take place from June 11 to 14 in Stockholm, Sweden.
As one of the most authoritative and influential top academic events in the global hematology field, the EHA Annual Congress brings together hematology professionals worldwide to share the latest cutting-edge research advances and breakthrough clinical data.
Key abstracts selected for poster presentations include:
UPDATED EFFICACY AND SAFETY OF OLVEREMBATINIB (HQP1351) AS SECOND-LINE THERAPY IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML)
Updated Efficacy and Safety of Olverembatinib (HQP1351) as Second-Line Therapy in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML)
- Abstract Number: PS1733
- First Author: Professor Li Weiming, Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
EFFICACY OF OLVEREMBATINIB IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) WITH PRIOR RESISTANCE TO PONATINIB OR ASCIMINIB AND ASXL1 MUTATIONS
Efficacy of Olverembatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) with Prior Resistance to Ponatinib or Asciminib and ASXL1 Mutations
- Abstract Number: PS1727
- First Author: Elias Jabbour, MD, Department of Leukemia, The University of Texas MD Anderson Cancer Center, USA
UPDATED RESULTS OF POLARIS-1 (PART 1), A GLOBAL REGISTRATIONAL PHASE 3 STUDY: OLVEREMBATINIB COMBINED WITH LOW-INTENSITY CHEMOTHERAPY IN NEWLY DIAGNOSED PH+ ALL
Updated Results of POLARIS-1 (Part 1), a Global Registrational Phase 3 Study: Olverembatinib Combined with Low-Intensity Chemotherapy in Newly Diagnosed Ph+ ALL
- Abstract Number: PS1479
- First Author: Professor Chen Suning, The First Affiliated Hospital of Soochow University
CORRELATION OF BASELINE CHARACTERISTICS WITH PROGNOSIS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) TREATED WITH LISAFTOCLAX (APG-2575) IN A PIVOTAL PHASE 2 STUDY
Correlation of Baseline Characteristics with Prognosis in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Lisaftoclax (APG-2575) in a Pivotal Phase 2 Study
- Abstract Number: PS1713
- First Author: Professor Zhou Keshu, Henan Cancer Hospital
SAFETY AND PRELIMINARY EFFICACY OF OLVEREMBATINIB (HQP1351) COMBINED WITH LISAFTOCLAX (APG-2575) IN PEDIATRIC PATIENTS WITH RELAPSED/REFRACTORY (R/R PH+ ALL): RESULTS OF A PHASE 1B STUDY
Safety and Preliminary Efficacy of Olverembatinib (HQP1351) Combined with Lisaftoclax (APG-2575) in Pediatric Patients with Relapsed/Refractory (R/R Ph+ ALL): Results of a Phase 1b Study
- Abstract Number: PS1473
- First Author: Zhang Jingliao, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
For all abstract information (including poster presentations and online publications), please visit the EHA official website.
About Ascentage Pharma
Ascentage Pharma (Nasdaq: AAPG; HKEX: 6855) is a comprehensive global biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative drugs to address unmet clinical needs of patients worldwide in oncology. The company has built a rich pipeline of innovative drug candidates, including inhibitors targeting key proteins in apoptosis pathways such as Bcl-2 and MDM2-p53, next-generation inhibitors for kinase mutants arising in cancer treatment, and protein degraders.
The company’s core product, Nailike®, is China’s first approved third-generation BCR-ABL inhibitor. It has been approved for the treatment of patients with chronic-phase chronic myeloid leukemia (CML-CP) and accelerated-phase CML (CML-AP) harboring the T315I mutation, as well as adult patients with CML-CP who are resistant and/or intolerant to first- and second-generation TKIs. All approved indications for this drug have been included in China’s National Reimbursement Drug List (NRDL). Currently, Ascentage Pharma is conducting three global registrational Phase 3 clinical studies for Nailike®: the POLARIS-1 study, authorized by the U.S. FDA and the European EMA, evaluating Nailike® in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL); the POLARIS-2 study, authorized by the U.S. FDA and the European EMA, evaluating Nailike® in pretreated adult patients with CML-CP; and the POLARIS-3 study, evaluating Nailike® in patients with SDH-deficient GIST.
The company’s another important product, Lishengtuo®, is a novel Bcl-2 inhibitor for the treatment of various hematologic malignancies. Lishengtuo® has been approved by China’s National Medical Products Administration (NMPA) for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have received at least one prior systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor. Currently, Ascentage Pharma is conducting four global registrational Phase 3 clinical studies for Lishengtuo®: the GLORA study, authorized by the U.S. FDA and the European EMA, evaluating Lishengtuo® in combination with a BTK inhibitor in CLL/SLL patients who have received prior BTK inhibitor therapy for more than 12 months and have suboptimal response; the GLORA-2 study, evaluating Lishengtuo® as first-line therapy in treatment-naïve CLL/SLL patients; the GLORA-3 study, evaluating Lishengtuo® as first-line therapy in newly diagnosed elderly or unfit AML patients; and the GLORA-4 study, authorized by the U.S. FDA and the European EMA, evaluating Lishengtuo® as first-line therapy in newly diagnosed intermediate- to high-risk MDS patients.
Leveraging its strong R&D capabilities, Ascentage Pharma has established a global intellectual property layout and entered into global collaborations with numerous leading biopharmaceutical companies such as Takeda, AstraZeneca, Merck Sharp & Dohme, Pfizer, and Innovent, as well as research collaborations with academic institutions including Dana-Farber Cancer Institute, Mayo Clinic, the National Cancer Institute, and the University of Michigan. For more information, please visit https://ascentage.com/
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as well as Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact in this press release may constitute forward-looking statements, including opinions, expectations, beliefs, plans, objectives, assumptions, or projections of Ascentage Pharma regarding future events, operating results, or financial condition.
These forward-looking statements are subject to numerous risks and uncertainties, as detailed in the documents filed by Ascentage Pharma with the U.S. Securities and Exchange Commission (SEC), including the “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” sections in the amended Registration Statement on Form F-1 filed on January 21, 2025, and the Annual Report on Form 20-F filed on April 16, 2025, the “Forward-Looking Statements” and “Risk Factors” sections in the IPO prospectus filed on October 16, 2019, and other documents we file from time to time with the SEC or HKEX. These factors could cause actual results, performance levels, operating results, or achievements to differ materially from those expressed or implied in the forward-looking statements. The statements in this forward-looking statement do not constitute a profit forecast by the company’s management.
Therefore, these forward-looking statements should not be regarded as predictions of future events. The forward-looking statements in this press release are based only on Ascentage Pharma’s current expectations and judgments regarding future developments and their potential impact, and represent views only as of the date of such statements. Ascentage Pharma undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.